InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

March 19, 2024

https://www.globenewswire.com/news-release/2024/03/19/2848459/0/en/InflaRx-to-Announce-Development-Plans-for-INF904-and-2023-Financial-Results-on-March-21-2024.html

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.